GENE ONLINE|News &
Opinion
Blog

.

Зеркало официального сайта всегда доступно для входа на Мостбет, даже при ограничениях. Скачать Mostbet – это шаг к удобству и азартным развлечениям.

Если вы ищете место для увлекательных ставок, обратите внимание на Joycasino, где лучшие предложения для игроков ждут вас.
2023-02-21| Trials & Approvals

CSL’s Hemgenix Wins First Gene Therapy Approval For Hemophilia In Europe

by Joy Lin
Share To

The European Commission (EC) has given conditional approval to CSL’s Hemgenix (etranacogene dezaparvovec), making it the first approved gene therapy for the treatment of severe and moderately severe hemophilia B in the European Union (EU) and European Economic Area (EEA).

“The approval of Hemgenix in Europe is the essence of great science delivering a medicine that we believe can transform the treatment paradigm for both people living with hemophilia B and the healthcare professionals who treat them,” said Dr. Bill Mezzanotte, Head of Research & Development and Chief Medical Officer, CSL.

Hemgenix is the result of a 2020 licensing collaboration between CSL Behring and uniQure. Under the terms of the agreement, uniQure received a $450 million upfront payment from CSL in May 2021 and could potentially receive up to $1.6 billion in milestones as well as tiered double-digit royalties up to the “low-twenties”.

“Hemgenix, and our partnership with uniQure, underscore CSL’s promise to pursue, develop and deliver disruptive innovations when patients can benefit, particularly in disease states we know well like hemophilia B,” said Dr. Bill. 

Reducing Annual Bleeds and Discontinuing Factor IX Prophylaxis

Hemophilia B is caused by an inherited deficiency in clotting Factor IX, which leads to spontaneous bleeding episodes in the body. People living with this condition require lifelong treatment of intravenous infusions of Factor IX, but Hemgenix offers them a chance to be free. The one-time treatment is designed to deliver a functional gene that restores the function of Factor IX. 

In an ongoing clinical trial called Hope-B, a single infusion of Hemgenix reduced the rate of annual bleeds by 54% during months 7-18. That number went up to 64% six months later. 96% of the 54 treated patients were able to discontinue Factor IX prophylaxis. The 24-month analysis in Hope-B continues to show a sustained and durable effect of Hemgenix. 

No serious adverse reactions to Hemgenix were identified in Hope-B; common reported side effects include liver enzyme elevations, flu-like symptoms, fatigue, and nausea. 

Hemgenix obtained US FDA approval in November 2022. In the UK, the Medicines and Healthcare products Regulatory Agency (MHRA) is currently receiving CSL’s submission for Hemgenix.

©www.geneonline.com All rights reserved. Collaborate with us: [email protected]
Related Post
FDA Approves Kebilidi: First Brain-Delivered Gene Therapy for Rare AADC Disease
2024-11-15
A Global Perspective on Australia’s Biotechnology Industry: Key Insights Ahead of AusBiotech 2024
2024-10-22
R&D
The Latest in Alzheimer’s Research: Restoring Cognitive Function with Nanotech, Gene Therapy, and Enhanced Brain Gamma Oscillations
2024-08-16
LATEST
Trump’s Trade War Shake-Up: How U.S. Tariffs Could Disrupt Global Pharma
2025-02-10
Precision Medicine Market Skyrocketing, Shaking the Industry with $470.53 Billion Expected by 2034
2025-02-10
Super Bowl LIX and the Biotech Sector: A New Arena for Engagement
2025-02-09
What the PlayStation Network Outage Can Teach the Biotech Industry
2025-02-08
Lilly’s Omvoh’s Two-Year Journey Confirms Lasting Impact on Crohn’s Disease Treatment
2025-02-08
Novo Nordisk Bets Big on CagriSema With A Heavyweight Move Planned for 2026
2025-02-07
Major Win – FDA Grants Fast Track Designation to Adicet Bio’s ADI-001 for Lupus Disease
2025-02-07
EVENT
2025-02-19
Healthcare Conference Taipei 2025
Taipei, Taiwan
2025-03-17
BIO-Europe Spring 2025
Milan, Italy
2025-04-21
World Vaccine Congress 2025
Washington, U.S.A
2025-04-21
World Vaccine Congress Washington 2025
Washington, U.S.A
2025-04-25
AACR Annual Meeting 2025
Chicago, U.S.A
Scroll to Top